BACKGROUND: Parameningeal (PM) site is a well-known adverse prognostic factor in children with localized rhabdomyosarcoma (RMS). To identify risk factors associated with outcome at this site, we pooled data from 1105 patients treated in 10 studies conducted by European and North American cooperative groups between 1984 and 2004. PATIENTS AND METHODS: Clinical factors including age, histology, size, invasiveness, nodal involvement, Intergroup Rhabdomyosarcoma Study (IRS) clinical group, site, risk factors for meningeal involvement (MI), study group, and application of radiotherapy (RT) were studied for their impact on event-free and overall survival (EFS and OS). RESULTS: Ten-year EFS and OS were 62.6 and 66.1% for the whole group. Patients without initial RT showed worse survival (10-year OS 40.8% versus 68.5% for RT treated patients). Multivariate analysis focusing on 862 patients who received RT as part of their initial treatment revealed four unfavorable prognostic factors: age <3 or >10 years, signs of MI, unfavorable site, and tumor size. Utilizing these prognostic factors, patients could be classified into different risk groups with 10-year OS ranging between 51.1 and 80.9%. CONCLUSIONS: While, in general, PM localization is regarded as an adverse prognostic factor, the current analysis differentiates those with good prognosis (36% patients with 0-1 risk factor: 10-year OS 80.9%) from high-risk PM patients (28% with 3-4 factors: 10-year OS 51.1%). Furthermore, this analysis reinforces the necessity for RT in PM RMS.
BACKGROUND: Parameningeal (PM) site is a well-known adverse prognostic factor in children with localized rhabdomyosarcoma (RMS). To identify risk factors associated with outcome at this site, we pooled data from 1105 patients treated in 10 studies conducted by European and North American cooperative groups between 1984 and 2004. PATIENTS AND METHODS: Clinical factors including age, histology, size, invasiveness, nodal involvement, Intergroup Rhabdomyosarcoma Study (IRS) clinical group, site, risk factors for meningeal involvement (MI), study group, and application of radiotherapy (RT) were studied for their impact on event-free and overall survival (EFS and OS). RESULTS: Ten-year EFS and OS were 62.6 and 66.1% for the whole group. Patients without initial RT showed worse survival (10-year OS 40.8% versus 68.5% for RT treated patients). Multivariate analysis focusing on 862 patients who received RT as part of their initial treatment revealed four unfavorable prognostic factors: age <3 or >10 years, signs of MI, unfavorable site, and tumor size. Utilizing these prognostic factors, patients could be classified into different risk groups with 10-year OS ranging between 51.1 and 80.9%. CONCLUSIONS: While, in general, PM localization is regarded as an adverse prognostic factor, the current analysis differentiates those with good prognosis (36% patients with 0-1 risk factor: 10-year OS 80.9%) from high-risk PM patients (28% with 3-4 factors: 10-year OS 51.1%). Furthermore, this analysis reinforces the necessity for RT in PM RMS.
Authors: Odile Oberlin; Annie Rey; José Sanchez de Toledo; Hélène Martelli; Meriel E M Jenney; Marcelo Scopinaro; Christophe Bergeron; Johannes H M Merks; Nathalie Bouvet; Caroline Ellershaw; Anna Kelsey; David Spooner; Michael C G Stevens Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: D S Hawkins; J R Anderson; C N Paidas; M D Wharam; S J Qualman; A S Pappo; K Scott Baker; W M Crist Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: W M Crist; J R Anderson; J L Meza; C Fryer; R B Raney; F B Ruymann; J Breneman; S J Qualman; E Wiener; M Wharam; T Lobe; B Webber; H M Maurer; S S Donaldson Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: S S Donaldson; J Meza; J C Breneman; W M Crist; F Laurie; S J Qualman; M Wharam Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: V Benk; C Rodary; S S Donaldson; F Flamant; H Maurer; I Treuner; M Carli; E Gehan Journal: Int J Radiat Oncol Biol Phys Date: 1996-10-01 Impact factor: 7.038
Authors: Richard Beverly Raney; Jane Meza; James R Anderson; Christopher J Fryer; Sarah S Donaldson; John C Breneman; Thomas J Fitzgerald; Edmund A Gehan; Jeff M Michalski; Jorge A Ortega; Stephen J Qualman; Eric Sandler; Moody D Wharam; Eugene S Wiener; Harold M Maurer; William M Crist Journal: Med Pediatr Oncol Date: 2002-01
Authors: J Buwalda; P F Schouwenburg; L E C M Blank; J H M Merks; M P Copper; S D Strackee; P A Voûte; H N Caron Journal: Eur J Cancer Date: 2003-07 Impact factor: 9.162
Authors: Jeff M Michalski; Jane Meza; John C Breneman; Suzanne L Wolden; Fran Laurie; MaryAnn Jodoin; Beverly Raney; Moody D Wharam; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Matthew M Ladra; Henry C Mandeville; Andrzej Niemierko; Timothy P Padera; Alison M Friedmann; Shannon M MacDonald; David Ebb; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: Meerim Park; Jun Ah Lee; Hye Young Jin; Joo-Young Kim; Jong Woong Park; June Hyuk Kim; Hyun Guy Kang; Seog Yun Park; Eun Young Park; Hyeon Jin Park; Byung Kiu Park Journal: J Cancer Res Clin Oncol Date: 2022-07-23 Impact factor: 4.322
Authors: Kirk D Wyatt; Suzi Birz; Douglas S Hawkins; Veronique Minard-Colin; David A Rodeberg; Monika Sparber-Sauer; Gianni Bisogno; Ewa Koscielniak; Gian Luca De Salvo; Martin Ebinger; Johannes H M Merks; Suzanne L Wolden; Wei Xue; Samuel L Volchenboum Journal: Pediatr Blood Cancer Date: 2022-08-15 Impact factor: 3.838
Authors: Odile Oberlin; Annie Rey; Kenneth L B Brown; Gianni Bisogno; Ewa Koscielniak; Michael C G Stevens; Douglas S Hawkins; William H Meyer; Trang H La; Modesto Carli; James R Anderson Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167
Authors: Adepitan A Owosho; Shih-Chiang Huang; Sonja Chen; Shruti Kashikar; Cherry L Estilo; Suzanne L Wolden; Leonard H Wexler; Joseph M Huryn; Cristina R Antonescu Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337
Authors: John T Lucas; Alberto S Pappo; Jianrong Wu; Daniel J Indelicato; Matthew J Krasin Journal: J Pediatr Hematol Oncol Date: 2018-07 Impact factor: 1.170